George F. Steinfels

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Diversa Pty Ltd. engages in the provision of investment management and financial services. It operates through Superannuation Services and Trustee Services segments. The Superannuation Services segment provides administration and promotion services to superannuation funds and the issue of group risk products. The Trustee Services segment involves in the third party superannuation trustee services and investment services. The company was founded by Matthew Morgan and Angus Craig on July 03, 1997 and is headquartered in Melbourne, Australia.

Endeavour Capital Ltd (Endeavour Capital) is a private equity firm founded in 1999 by Neville Jordan. The firm is headquartered Wellington, New Zealand.

MDNA Life Sciences, Inc. engages in the development of molecular tests based on the mitochondrial genome. It focuses on the development and commercial application of mitochondrial DNA based biomarkers for the early detection of prostate, ovarian and lung cancers, and endometriosis. The company was founded by Mark Birch-Machin, Robert Thayer, and Ryan L. Parr in 2001 and is headquartered in West Palm Beach, FL.